A Swedish group of doctors and researchers are working to develop new tools and models to more effectively manage and treat patients with Parkinson’s disease. The group, led by Per Odin, MD, PhD, professor at Lund Universit’s strategic research area Multipark and senior attending physician at Skåne University Hospital,…
Two scientists at Yale University were awarded $2 million from the Michael J. Fox Foundation to conduct the first clinical trial investigating the use of ketamine — a powerful anesthetic — as a treatment for depression in people with Parkinson’s disease. The study will be led by Sophie…
An oral candidate therapy for Parkinson’s disease called GT-02287 lowered the levels of alpha-synuclein accumulation and inflammation, and lessened behavioral deficits in animal models of the disease. “We are working diligently to advance this breakthrough compound to the clinic and bring it one step closer to meeting the currently unaddressed needs…
Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a potential therapy for Parkinson’s disease. This follows the approval by the U.S. Food and Drug Administration of Fascinate’s request for such a trial, in the form of an investigational new…
The American Academy of Neurology (AAN) has issued a new group of guidelines designed to aid clinicians in prescribing the most effective and appropriate dopaminergic medications — those that increase or mimic dopamine — to patients in the early stages of Parkinson’s disease. The new guidelines, endorsed by…
Mitochondrial dysfunction in dopamine-producing brain cells is sufficient to cause Parkinson’s disease, according to a new study done in mice. The study, “Disruption of mitochondrial complex I induces progressive parkinsonism,” was published in Nature. Parkinson’s is caused by the death and dysfunction of dopamine-producing (dopaminergic) neurons.
An interdisciplinary research team from William and Mary University and Virginia Commonwealth University (VCU) are working on artificial intelligence programming to help develop a wearable device to treat freezing of gait (FoG), the temporary inability to move while walking, which is a motor symptom of Parkinson’s disease. “Freezing of…
Applications are open for the Parkinson’s Foundation 2022 community grant cycle, with $1 million to be awarded to help fund community-based health, wellness, and education programs supporting those affected by Parkinson’s disease. Since 1957, the Foundation has invested more than $400 million toward Parkinson’s research and clinical care.
A heightened fear of falling — common for Parkinson’s patients due to balance and walking problems — is significantly associated with greater swallowing difficulties among these people, a small study shows. Notably, this association was observed even when adjusting for potential influencing factors such as disease duration, suggesting these symptoms…
A committee of the European Medicines Agency (EMA) has issued a negative opinion for Nouryant (istradefylline) — approved as Nourianz in the U.S. — as an add-on medication for treating “off” episodes in those with Parkinson’s disease in the European Union. The Committee for Medicinal Products for Human Use (CHMP) is maintaining…
Get regular updates to your inbox.
